PIK3CA Q546E

CI-VAR-00003545Explore in graph →NP_006209.2:p.Gln546GluNM_006218.3:c.1636C>GClinVar 13654 CIViC 886 rs121913286

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
PIK3CA Q546E	PI103	Predictive	D	Supports Sensitivity Response	—	submitted	EID2090 In H460, a gefitinib-resistant NSCLC cell line that harbors PIK3CA mutations, the dual PI3Kalpha/mTOR inhibitor PI103 reduced cell growth and increased the expression of the tumor suppressor p53 compa… (full text at CIViC) PMID 19513541 · Zou et al., 2009 · Open in CIViC	civic
Malignant Breast Neoplasm2
PIK3CA Q546E OR PIK3CA Q546R	Alpelisib + FulvestrantCombination	Predictive	A	Supports Sensitivity Response	5	accepted	EID7316 In a phase 3 trial, patients with hormone receptor positive, HER2 receptor negative breast were allocated to alpelisib plus fulvestrant or placebo plus fulvestrant. Patients were enrolled into two coh…

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
13654	Likely pathogenic	criteria provided, single submitter	1	Breast adenocarcinoma; PIK3CA related overgrowth syndrome	somatic	2	Sep 09, 2024	clinvar

HER2 Negative Breast Cancer1unmapped disease
PIK3CA Q546E	Capivasertib + FulvestrantCombination	Predictive	A	Supports Sensitivity Response	2	submitted	EID12190 In a phase 3 trial (NCT04305496) of 708 patients with advanced HR+ HER2- breast cancer, the combination of the AKT inhibitor capivasertib and the estrogen receptor degrader fulvestrant resulted in sig… (full text at CIViC) PMID 37256976 · Turner et al., 2023 · Open in CIViC	civic